With the Technology Fast 50 Award Deloitte annually honors the fastest-growing technology companies in the sectors of Hardware, Software, Communications, Media & Entertainment, Healthcare & Life Sciences, Environmental Technology and FinTech.

ADVITOS is the only listed MedTech company of the Technology Fast 50 Award and achieves the 27^th place.

The ranking is based on the growth in sales over the last four financial years (2015 – 2018). ADVITOS was able to record a growth of 680 percent in this period. That was achieved with the commercialization of the inhouse-developed, CE-marked and worldwide patented ADVOS technology (ADVanced Organ Support) – the only therapy worldwide offering multi organ support integrated in one single device.

“We are very excited to be listed in the prestigious Deloitte Technology Fast 50 2019.”, says Assoc. Prof. Dr. med. Bernhard Kreymann, inventor of the ADVOS procedure, founder and CEO of ADVITOS GmbH. “It is a great recognition for the entire team who has worked very hard to make this happen. Further, this will give us visibility to investors and new customers which in turn will help us with further growth and the establishment of our innovative therapy in other markets.”

About ADVITOS – ADVITOS developed the CE-marked and worldwide patented ADVOS technology (ADVanced Organ Support) – the only therapy worldwide offering multi organ support integrated in one single device. ADVOS improves survival of ICU patients by simultaneously supporting all three main detoxification organs: the liver, the lung and the kidney. The solution allows fluid-based elimination of: water-soluble toxins (kidney), protein-bound toxins (liver and kidney), and CO₂ (lungs). In addition, ADVOS enables treatment of acid-base disbalances through patient individual correction of the blood pH value. The ADVOS therapy is used in intensive care units at 20 leading hospitals throughout Germany and is on its way to penetrating the international market.